ReviewFrontiers in medicine2026
The role of dermatological manifestations in the early diagnosis of Fabry disease: a scoping review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fabry disease (FD) is a rare X-linked lysosomal storage disorder characterized by the progressive accumulation of globotriaosylceramide in multiple organs. Despite the availability of disease-specific therapies, diagnosis is often delayed due to heterogeneous and nonspecific manifestations. This review aimed to synthesize current evidence on dermatological manifestations of FD and their potential contribution to earlier disease recognition. A scoping review was conducted following the Arksey and O'Malley framework and the PRISMA-ScR guidelines. PubMed, Scopus, and Web of Science were searched for relevant studies, and additional records were identified through snowballing of reference lists from retrieved reviews. Thirty-two records were included, comprising data on 2,209 patients, with detailed patient-level information available for 146 individuals. Dermatologists were involved in the diagnostic process in 66% of the included studies, and 69% of these reported a potential contribution of dermatological evaluation to earlier disease recognition. Angiokeratomas (88% of included studies) and hypohidrosis (50% of included studies) were the most frequently reported cutaneous manifestations. Skin biopsy or histopathological examination was reported in 59% of included studies and was the most frequently reported dermatological investigative technique. Among patients with dermatological manifestations and available diagnostic delay information, 66% had a reported diagnostic delay of 1-10 years. These findings suggest that dermatological manifestations may contribute to earlier recognition of FD. However, they should be interpreted cautiously given the descriptive nature of the available evidence, the absence of an appropriate comparator group, and the potential influence of selection and publication bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.